Ayala Pharmaceuticals (NASDAQ:ADXS) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS – Free Report) in a research note issued to investors on Wednesday. The brokerage issued a sell rating on the stock.

Ayala Pharmaceuticals Price Performance

Ayala Pharmaceuticals stock opened at $0.03 on Wednesday. The firm has a market cap of $1.15 million, a price-to-earnings ratio of 0.00 and a beta of 1.72. Ayala Pharmaceuticals has a 52 week low of $0.00 and a 52 week high of $1.49. The business’s 50-day moving average price is $0.03 and its 200 day moving average price is $0.24.

Ayala Pharmaceuticals Company Profile

(Get Free Report)

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.

Further Reading

• Five stocks we like better than Ayala Pharmaceuticals
• ETF Screener: Uses and Step-by-Step Guide
• 3 Micro-Caps Set for Major Moves: Balancing Risk and Opportunity
• What Are Growth Stocks and Investing in Them
• Autodesk Named a “Top Pick” by Morgan Stanley—Is It Time to Buy?
• The 3 Best Fintech Stocks to Buy Now
• 4 Quirky ETFs With Big Potential for Impressive Gains